PA9159 clinical trials
How each study uses PA9159 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PA9159 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Anhui Palo Alto Pharmaceuticals, Inc. (6)
Studies
Open first, then newest update. How each study uses PA9159 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial AsthmaRecruitingPhase 2Anhui Palo Alto Pharmaceuticals, Inc.NCT07326995Written as PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days
- Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial AsthmaRecruitingPhase 2Anhui Palo Alto Pharmaceuticals, Inc.NCT07324707Written as PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days
- Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult SubjectsCompletedPhase 1Anhui Palo Alto Pharmaceuticals, Inc.NCT07345442Written as PA9159 nasal spray solution, 80 μg one day treatment
- Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult SubjectsCompletedPhase 1Anhui Palo Alto Pharmaceuticals, Inc.NCT06916273Written as PA9159 Inhalation aerosol, 60 μg one day treatment
- Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic RhinitisCompletedPhase 2Anhui Palo Alto Pharmaceuticals, Inc.NCT05234580Written as PA9159 nasal spray solution, 10 μg once daily for 14 days
- Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult SubjectsCompletedPhase 1Anhui Palo Alto Pharmaceuticals, Inc.NCT05170763Written as PA9159 nasal spray solution, 10 μg one day treatment